Global Imaging Biomarkers Market - Forecast (2022-2027)

Global Imaging Biomarkers Market Overview

Global Imaging Biomarkers Market size reached $6,642 million in 2021, growing at a CAGR of 14.1% during the forecast period 2022-2027. A biomarker is a biological molecule found in tissue, blood, or other body fluids, which marks the presence of a normal or an abnormal process, or of a condition or disease. An imaging biomarker is a biologic feature, or biomarker detectable in an image. In medicine, an imaging biomarker is a feature of an image relevant to a patient's diagnosis. Imaging biomarkers (IBs) are vital in the treatment of cancer, Alzheimer and other diseases. Clinical TNM stage, objective response, and left ventricular ejection fraction are all IBs utilized in cancer treatment. Imaging biomarkers are used for the real visualization of medication pharmacodynamics effects and treatment responses. It is essential for ensuring patient safety and determining the efficacy of a treatment. Imaging biomarkers offer non-invasive methods that can be used in both labs and clinics. The rise in illness awareness, greater screening and awareness among patients, and technological breakthroughs such as virtualization of imaging biomarkers and big data technologies and increased service improvements are the factors that are set to drive the growth of the Imaging Biomarkers Market for the period 2022-2027.

Report Coverage

The report: Global Imaging Biomarkers Market - Forecast (2022-2027)” covers an in-depth analysis of the following segments of the Global Imaging Biomarkers Market.

By Technology: Positron Emission Tomography (PET), Ultrasound, Magnetic Resonance Imaging, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and Others.

By Application: Personalized Medicine, Drug Discovery and Development, Molecular Diagnostics, Drug Formulation, Disease Diagnosis, Forensic Applications, and Others.

By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, the North America Imaging Biomarkers Market accounted for the highest revenue share in 2021, and it is poised to dominate over the period 2022-2027 owing to the growing focus on technological advancements like virtualization of imaging biomarkers, and technologies like Big Data in the region.
• The ability to enable the characterization of patient populations to which new drugs reach intended targets is driving the Drug Discovery and Development segment. However, the difficulties in developing reliable imaging biomarkers are one of the major factors that are said to reduce the growth of the Imaging Biomarkers Market.
• In addition, according to the Alzheimer's Disease Facts and Figures Report, more than 5.8 million persons in America suffered from dementia caused by Alzheimer's disease in 2019, with the majority of patients being over 75 years old, which in turn is contributing to the growth of the Imaging Biomarkers Market.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Imaging Biomarkers Market report.

Global Imaging Biomarkers Market Segment Analysis - By Technology:

Based on Technology, the Magnetic Resonance Imaging segment accounted for the largest revenue market share in 2021 for Global Imaging Biomarkers Market as they are more dynamic and can be adjusted to derive several parameters based on several intrinsic features of tissue, such as T1- and T2 relaxation times, proton density, diffusion, and water-fat fraction. Magnetic Resonance Imaging is a useful diagnostic tool for detecting disorders such as lesions in the spine, cancers, and strokes that affect the blood vessels and brain. The growing focus on developing improved MR image processing techniques to find MR-related biomarkers that are utilized to improve the accuracy of clinical diagnosis of Alzheimer's disease is driving the growth of the Imaging Biomarkers Market. The Computed Tomography segment is predicted to grow with the fastest CAGR of 17.2% in the forecast period 2022-2027. Fully automated quantitative tissue biomarkers obtained from CT scans outperform existing clinical indicators for presymptomatic risk classification for potential major adverse events and add opportunistic value to CT images used for other purposes is supporting the segment growth.

Global Imaging Biomarkers Market Segment Analysis - By Application:

Based on Application, the Disease Diagnosis segment accounted for the largest revenue market share in 2021 for Imaging Biomarkers Market. The precision of the measurements in disease diagnosis is influenced by the image acquisition parameters (different centers, vendors, protocols, patient preparation), and image processing methods (computer algorithm, influence of human interaction) are fuelling segment growth. The Drug Discovery and Development segment is predicted to grow with the fastest CAGR of 17.7% in the forecast period 2022-2027. This is owing to their ability to enable the characterization of patient populations to which new drugs reach intended targets. Imaging modalities such as magnetic resonance imaging, computed tomography, and positron emission tomography offer significant insights into the bioactivity, pharmacokinetics, and dosing of drugs, in addition to supporting registration applications. Imaging biomarkers are very familiar to drug developers such as bone mineral density in osteoporosis, left ventricular ejection fraction in cardiology; objective tumor response carotid intima-media thickness in atherosclerosis, which is driving the growth of the Imaging Biomarkers Market.

Global Imaging Biomarkers Market Segment Analysis - By Geography

Based on Geography, North America Imaging Biomarkers accounted for the 41% revenue share in 2021. The growing awareness of the disease, the increased screening, and the rising advancements are set to drive the growth of the regional market. The increased technological advancements like virtualization of imaging biomarkers, and technologies like Big Data are making way for highly complex imaging techniques. Scientists in the region are exploring more about the structural and functional differences of neurological diseases. Moreover, there has been an increase in biobanks which have helped to address unmet needs in oncology, neuroscience, and cardiovascular disease. An increasing number of research and development activities for improving the effectiveness of neurological Biomarkers are driving the growth of the Imaging Biomarkers Market. The Asia-Pacific market is poised to grow with the fastest CAGR in the forecast period 2022-2027. The rapid increase in health insurance coverage is the key driving factor as they ensure access to high-quality care while protecting high medical expenses. The rising prevalence of colon or colorectum cancer among men and women both and growing technological developments in Spain are further driving the Imaging Biomarkers market.

Global Imaging Biomarkers Market Drivers

Rising Incidences Of Chronic Diseases Such As Cancer, Including Lung, Liver, And Stomach Cancer Aids In Market Growth:

The demand for Imaging Biomarkers is growing owing to the rising number of cancer cases, as Imaging biomarkers (IBs) are essential in the treatment of cancer patients. Clinical TNM stage, objective response, and left ventricular ejection fraction are all IBs utilized in cancer daily. Biomarkers like CT, MRI, PET, and ultrasonography are widely employed in cancer research and medication development. The rising number of cancer cases is predicted to increase the demand for improved personalized cancer medicines to treat patients effectively, which is propelling the growth of the Imaging Biomarkers Market.

The Recognition Of Imaging Biomarkers To Play A Larger Role In The Future Of Tailored Medicine Is Boosting The Market Growth:

Imaging Biomarkers, which use genomic data to help forecast certain health conditions, are well-known in the healthcare business and have paved the way for a new era of personalized medicine. These biomarkers help frontline clinicians improve patient care in ways that lead to preventive measures, such as predicting the likelihood of developing certain types of cancer, but they also help life science companies find research study candidates who are most likely to succeed when given a specific therapy. Imaging biomarkers that are developed through the science of radionics are playing a larger role in the future of tailored medicine development are now recognized in the business, which is driving the growth of the Imaging Biomarkers Market.

Global Imaging Biomarkers Market Challenge:

Difficulties In Developing Reliable Imaging Biomarker Is Hindering The Market Growth:

The lack of precise, non-invasive, image-based tissue characterization; the micro resolution, which allows for earlier identification of a lesion, a microscopic metastasis (less than 0.2mm), or the exact borders of a detected lesion is restricting the market growth. The development of reliable imaging biomarkers is fraught with difficulties. It necessitates proving that one or more functional metrics accurately reflect the biology of interest, as well as identifying a measurement procedure that can be used in a consistent and repeatable manner. The measurement method's specification can be difficult, like in the case of MRI, where there are many experimental variables. The signal's influence, as a result, optimizing and then standardizing the task of developing functional imaging measurement methods is difficult, which is one of the major factors that is estimated to reduce the growth of the Imaging Biomarkers market.

Global Imaging Biomarkers Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Global Imaging Biomarkers Market. Global Imaging Biomarkers Market top 10 companies are:

1. Siemens Healthineers

2. ICON Plc

3. Invicro LLC

4. Median Technologies

5. PI Solutions Group GmbH

6. IXICO plc

7. Bioxydyn Ltd.

8. Zionexa

9. Imabiotech

10. BRAINOMIX

Recent Developments

• In June 2021, ImaBiotech Group has expanded its Bioanalytical Pharmaceutical Services in North America with Pyxant Labs Colorado. The company has expanded with the integration of the expertise, innovation, and analytical platforms of the companies. The expansion is done to form a leading global bioanalytical services provider by encompassing unique proprietary drug and biomarker imaging to provide a unique offering to pharmaceutical companies.
• In March 2021, IXICO plc has entered into a partnership with Cyclerion Therapeutics, Inc. The partnership is made to support the company's Phase IIa clinical trial to investigate CY6463 for the treatment of individuals with Alzheimer's disease. The partnership objective is to provide advanced neuroimaging solutions.
• In March 2021, Invicro LLC has entered into a partnership with Amazon Web Services, Inc. to support the build-out of the company’s LATTICETM initiative. It is a ground-breaking integrated diagnostic data platform. LATTICETM combines genomics and radiology data along with other critical information to uncover clinically relevant biomarkers and create the next generation of diagnostic tests.